Lamivudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. LAMIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Lamivudine under HS 29349990 and SITC 51579. As of Q4 2014, LAMIVUDINE remains the US FDA Preferred Term for this commodity. Lamivudine bears US NLM identifiers UMLS ID C0209738 and NCI Concept Code C1471. SMILES: C1CN(C(=O)NC1N)[C@@H]2CS[C@@H](O2)CO.